Adage Capital Partners Gp, L.L.C. Infla Rx N.V. Transaction History

Adage Capital Partners Gp, L.L.C.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 14, 2019	SELL	$3.06 - $51.61 $6.95 Million - $117 Million	-2,271,959 Closed	0 $0
Q1 2019 May 15, 2019	SELL	$31.16 - $48.62 $12.7 Million - $19.9 Million	-409,000 Reduced 15.26%	2,271,959 $85.9 Million
Q4 2018 Feb 14, 2019	BUY	$23.33 - $36.37 $3.01 Million - $4.69 Million	129,000 Added 5.05%	2,680,959 $97.5 Million
Q3 2018 Nov 14, 2018	BUY	$29.34 - $35.0 $4.88 Million - $5.82 Million	166,300 Added 6.97%	2,551,959 $87.6 Million
Q2 2018 Aug 14, 2018	BUY	$27.33 - $41.46 $27.1 Million - $41.1 Million	991,527 Added 71.12%	2,385,659 $76.9 Million
Q1 2018 May 15, 2018	BUY	$20.21 - $32.0 $16.9 Million - $26.8 Million	837,677 Added 150.54%	1,394,132 $40.2 Million
Q4 2017 Feb 14, 2018	BUY	$14.55 - $23.99 $8.1 Million - $13.3 Million	556,455	556,455 $11.7 Million

13.2M

5.2K

Ticker IFRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,203,800
Market Cap $61M
Description
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a nov...

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.